지엘팜텍

204840KOSDAQ생활용품 도매업

42.0 / 100

Reference Date: 2026-04-13

Financial Score9.5 / 40

News Sentiment16.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is above the industry average but the high debt ratio poses financial risk. Declined 5.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GELPAMTEK primarily operates in pharmaceutical R&D services and has expanded into drug distribution and marketing. Its subsidiary, GELPHARMA, focuses on pharmaceutical manufacturing and sales, with key products including gastritis treatments, neuropathic pain medications, and specialty drugs. The company also generates revenue through technology fees and royalties from licensing its improved new drug technologies.

Number of Employees

32people

Average Salary

46.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

6426.61Industry Average 14.250.0Point

451.0x industry avg (risky)

PBR

4.03Industry Average 0.750.0Point

5.4x industry avg (risky)

ROE

0.06Industry Average 0.064.0Point

In line with industry avg

Debt Ratio

37.41Industry Average 11.050.0Point

3.4x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲80.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.7% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 2Neutral 0Negative 0Average Sentiment Score 90

Positive
지엘팜텍, 실적으로 체질개선 증명…"개량신약 선순환 구조 정착"
지엘팜텍이 지난해 역대 최고 실적을 기록하며 체질을 개선했고, 올해는 개량신약 중심으로 사업 구조를 재편하며 지속 성장의 토대를 마련하는 데 집중할 계획입니다.
Positive
지엘팜텍, 지난해 역대 최대 매출 및 흑자 전환 성공
지엘팜텍은 지난해 역대 최대 매출 353억원과 창사 이래 첫 영업이익 3억원, 당기순이익 1250만원을 기록하며 흑자 전환에 성공했습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 1,035Won52-week high 1,42752-week low 1,008

1-month return2.0Point

1m -5.48% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-18